IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

NCT04982705 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: [Part 1.1] IDG-16177
DRUG: [Part 1.1] Placebo of IDG-16177
DRUG: [Part 2] Sitagliptin
DRUG: [Part1.2] IDG-16177
DRUG: [Part 2] IDG-16177
DRUG: [Part 1.2] Placebo of IDG-16177
DRUG: [Part 2] Placebo of IDG-16177

Sponsor

IlDong Pharmaceutical Co Ltd